Mega Lifesciences PCL (BKK:MEGA)

Mega Lifesciences PCL Balance Sheet

Financials in millions THB. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3,559	3,463	2,357	2,453	2,198	1,006
Short-Term Investments	350.14	395.19	365.05	345.55	342.64	225.85
Cash & Short-Term Investments	3,909	3,858	2,722	2,799	2,540	1,232
Cash Growth	17.92%	41.74%	-2.76%	10.18%	106.14%	-16.02%
Accounts Receivable	2,764	2,975	3,314	3,107	2,557	2,507
Other Receivables	351.36	152.53	158.28	180.15	164.18	74.68
Receivables	3,116	3,128	3,472	3,287	2,721	2,581
Inventory	3,004	3,033	3,377	4,109	3,823	3,489
Prepaid Expenses	-	60.43	58.59	60.14	53.43	43.95
Other Current Assets	120.34	147.7	360.23	334.95	162.8	240.19
Total Current Assets	10,150	10,227	9,990	10,590	9,301	7,587
Property, Plant & Equipment	2,220	2,213	2,225	2,151	2,103	2,214
Long-Term Investments	40.25	40.39	221.15	222.88	214.79	194.47
Goodwill	444.23	449	456.24	465.88	476.25	437.32
Other Intangible Assets	868.92	869.72	862.23	863.31	876.89	875
Long-Term Deferred Tax Assets	319.79	299.89	278.95	250.32	210.41	175.03
Other Long-Term Assets	321.21	111.52	81	103.49	89.75	74.27
Total Assets	14,364	14,210	14,115	14,646	13,272	11,557
Accounts Payable	1,556	1,685	1,925	2,793	2,527	2,048
Accrued Expenses	837.17	1,102	1,140	1,604	1,283	823.52
Short-Term Debt	268.4	287.58	76	229.18	168.18	499.49
Current Portion of Leases	62.36	63.83	43.78	82.96	56.21	36.67
Current Income Taxes Payable	229.12	145.54	108.45	204.18	185.86	160.73
Other Current Liabilities	657.15	630.65	1,133	624.44	633.02	660.61
Total Current Liabilities	3,611	3,914	4,427	5,538	4,853	4,229
Long-Term Leases	146.36	139.83	132.06	108.73	131.94	111.31
Long-Term Deferred Tax Liabilities	0	1.05	2.14	-	-	0.98
Other Long-Term Liabilities	-	-	-	-	-	0.33
Total Liabilities	4,046	4,333	4,813	5,870	5,247	4,578
Common Stock	435.94	435.94	435.94	435.94	435.94	435.94
Additional Paid-In Capital	2,305	2,305	2,305	2,305	2,305	2,305
Retained Earnings	8,279	7,830	7,210	6,655	5,766	4,752
Comprehensive Income & Other	-701.76	-693.31	-648.11	-618.9	-503.97	-534.41
Total Common Equity	10,318	9,877	9,302	8,777	8,003	6,958
Minority Interest	0.12	0.08	0.02	0.07	22.3	21.29
Shareholders' Equity	10,318	9,877	9,302	8,777	8,025	6,979
Total Liabilities & Equity	14,364	14,210	14,115	14,646	13,272	11,557
Total Debt	477.12	491.24	251.84	420.87	356.33	647.47
Net Cash (Debt)	3,432	3,367	2,470	2,378	2,184	584.84
Net Cash Growth	15.09%	36.31%	3.86%	8.89%	273.44%	1.37%
Net Cash Per Share	3.94	3.86	2.83	2.73	2.50	0.67
Filing Date Shares Outstanding	871.87	871.87	871.87	871.87	871.87	871.87
Total Common Shares Outstanding	871.87	871.87	871.87	871.87	871.87	871.87
Working Capital	6,539	6,312	5,563	5,052	4,448	3,358
Book Value Per Share	11.83	11.33	10.67	10.07	9.18	7.98
Tangible Book Value	9,005	8,558	7,984	7,447	6,650	5,645
Tangible Book Value Per Share	10.33	9.82	9.16	8.54	7.63	6.47

Updated Feb 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.